Effect of Treatment of Children at the age of 6-12 years with the Allergic Rhinitis Which is Followed by Cough by a Combination Loratadin / Ambroxol within 10 days

Summary:
The given clinical trial was planned with the purpose to determine efficiency and safety of treatment of children with a new combination of a loratadin of 1,0 mg/ml and ambroxol of 6 mg/ml in the solution prescribed 2 times per day (in each 12 h) within 10 days, in comparison with treatment of the specified medicines ( loratadin and ambroxol) separately. The trial was conducted in unit of pediatrics of Hospital Escandón in the federal district of Mexico City. The trial was conducted within 6 months and was double blind randomized prospective and comparative. 123 children at the age of 6–12 years with the diagnosed allergic rhinitis which wass followed by cough took part in it. For determination of efficiency of treatment in each case an assessment of clinical development was carried out of the following symptoms: sneezing, a rhinorrhea, excessive tearing, nasal itch, cough and its prevalence in day or night time. Also an existence and expression of a retronasal syndrome, congestion of a nose and set of all clinical signs was considered. Besides, the researcher and patients estimated clinical efficiency of treatment. The results showed that the combination of loratadin / ambroxol was more effective in all respects estimates in comparison with each of its components applied separately, that was especially brightly expressed during the period between the 5th and 10th days of treatment. It proves that fact, that loratadin, besides immediate impact on H1 receptors, has anti-inflammatory effects which amplify at 10-day treatment, in connection with it, it can be recommended that treatment period during allergic rhinitis complication was 10 and more days.